A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Upcoming Events


Arena International Announces the Brand New Direct-to-Patient and Virtual Clinical Trials Digital Experience

   by Kadin Luong    251
Arena International Announces the Brand New Direct-to-Patient and Virtual Clinical Trials Digital Experience

London – Arena International announced today the first-ever Direct-to-Patient and Virtual Clinical Trials (https://arena-international.com/dtpvirtual/) will be held as a Digital Experience on Thursday, 9 July 2020. As COVID-19 has forced the market to move towards decentralized and remote models, this event provides the perfect opportunity for clinical trial professionals to hear, meet and learn from top-class speakers around the world to discuss challenges and innovations in this critical time.

Greenphire Enhances ClinCard to Further Support Remote Clinical Trials

   by Greenphire    282

As the COVID-19 pandemic continues to limit movement all over the world, clinical trials have had to adapt by leveraging methodologies typically associated with hybrid or remote clinical trial designs. The alternative would be to suspend the trial and interrupt care for enrolled patients, something that according to NPR, has been done to more than 400 studies since March 1, 2020.

To help keep trials active and patients engaged during trial disruption, Greenphire, the global leader in financial software for clinical trials, today announced that it has enhanced its award-winning payment and reimbursement solution, ClinCard, to include additional capabilities to support decentralized clinical trials due to COVID-19 interruptions.

“As the landscape for clinical trials evolves, we’re beginning to see a need for remote payment capabilities. We heard from over 1,800 site personnel and over 80% said that providing a small payment following a virtual visit would improve the likelihood of participants staying in a clinical trial,” said Kyle Cunningham, Chief Product Officer of Greenphire. “It’s of utmost importance to keep clinical trials running in this uncertain time. As a company dedicated to removing barriers to both sites and patients, we’re thrilled to offer these new capabilities for our ClinCard solution so that patients can stay engaged and enrolled in trials and sites can continue their critical work.”

Challenges in Supply and Partner-Sourcing for Stem-Gene – Clinical Trial Supply – A Virtual Experience

   by Arena International Events Group    306
Challenges in Supply and Partner-Sourcing for Stem-Gene – Clinical Trial Supply – A Virtual Experience

London – On Tuesday, (12th May) CTS Virtual (https://arena-international.com/ctsvirtual/),  will host new key sessions on Clinical Trial Supply 2020 Trends, Stem-gene Clinical Trials and many more.

As modern medicine advances, the global clinical supply chain needs to keep up, and the expanding market for stem-cell and gene therapy is making this increasingly complex for companies doing research and development in these areas. The therapeutic potential for stem-cell and gene products is vast, with targeted personalized medicine to suit the individual needs of sick patients, but running clinical supply operations in these fields can come at a high cost and requires detailed planning.

Top AI in Pharma and Healthcare Conferences in 2020 You Can’t Miss

   by Andrii Buvailo    22039
Top AI in Pharma and Healthcare Conferences in 2020 You Can’t Miss

Artificial intelligence (machine learning and deep learning, to be more specific) has become widely discussed topics in the area of life sciences and healthcare over the last several years and the excitement keeps growing. While a lot of pharmaceutical companies and healthcare organizations express considerable interest in possible new opportunities, associated with the use of artificial intelligence for early drug discovery, clinical trial optimization, and business intelligence, a considerable gap still exists when it comes to understanding new technologies by pharmaceutical professionals and leaders. The key questions here are these:

  • What machine learning / AI can and can’t do for the pharmaceutical industry

  • What should be done to harness practical and measurable value out of machine learning / AI?

  • How it should be done and what are the timelines for getting returns on investments?